| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Cesarean Section | 30 | 2024 | 402 | 5.120 |
Why?
|
| Embolism, Amniotic Fluid | 12 | 2020 | 31 | 4.770 |
Why?
|
| Heart Rate, Fetal | 14 | 2022 | 63 | 4.750 |
Why?
|
| Maternal Mortality | 20 | 2020 | 81 | 4.470 |
Why?
|
| Pregnancy | 119 | 2024 | 7570 | 4.130 |
Why?
|
| Hypertension, Pregnancy-Induced | 8 | 2024 | 77 | 3.880 |
Why?
|
| Pregnancy Complications | 17 | 2024 | 553 | 3.700 |
Why?
|
| Obstetrics | 16 | 2019 | 240 | 3.580 |
Why?
|
| Delivery, Obstetric | 16 | 2024 | 260 | 3.070 |
Why?
|
| Arabidopsis | 11 | 2013 | 94 | 3.020 |
Why?
|
| Venous Thromboembolism | 9 | 2024 | 185 | 2.960 |
Why?
|
| Arabidopsis Proteins | 12 | 2013 | 60 | 2.910 |
Why?
|
| Postpartum Hemorrhage | 12 | 2024 | 102 | 2.730 |
Why?
|
| Pregnancy Complications, Cardiovascular | 7 | 2019 | 105 | 2.360 |
Why?
|
| Pre-Eclampsia | 8 | 2022 | 227 | 2.200 |
Why?
|
| Fetal Monitoring | 7 | 2022 | 58 | 2.040 |
Why?
|
| Obstetric Labor Complications | 7 | 2018 | 98 | 2.030 |
Why?
|
| Labor, Obstetric | 8 | 2021 | 97 | 1.930 |
Why?
|
| Placenta Accreta | 12 | 2024 | 169 | 1.690 |
Why?
|
| Labor, Induced | 5 | 2014 | 34 | 1.650 |
Why?
|
| Female | 123 | 2024 | 71893 | 1.590 |
Why?
|
| Meristem | 7 | 2013 | 7 | 1.510 |
Why?
|
| Oxytocin | 4 | 2014 | 74 | 1.380 |
Why?
|
| Gestational Age | 14 | 2024 | 1229 | 1.340 |
Why?
|
| Cardiotocography | 3 | 2021 | 20 | 1.240 |
Why?
|
| Pulmonary Embolism | 6 | 2015 | 189 | 1.240 |
Why?
|
| Blood Loss, Surgical | 5 | 2024 | 158 | 1.190 |
Why?
|
| Reproductive Techniques, Assisted | 3 | 2021 | 76 | 1.190 |
Why?
|
| Humans | 128 | 2024 | 134084 | 1.160 |
Why?
|
| Maternal Death | 3 | 2016 | 10 | 1.160 |
Why?
|
| Pregnancy Outcome | 12 | 2021 | 629 | 1.140 |
Why?
|
| Intracranial Hemorrhages | 3 | 2014 | 81 | 1.120 |
Why?
|
| Oxytocics | 5 | 2014 | 28 | 1.120 |
Why?
|
| Antihypertensive Agents | 6 | 2024 | 410 | 1.080 |
Why?
|
| Practice Patterns, Physicians' | 4 | 2018 | 772 | 1.070 |
Why?
|
| Heparin, Low-Molecular-Weight | 2 | 2017 | 26 | 1.050 |
Why?
|
| Gynecology | 3 | 2017 | 129 | 1.020 |
Why?
|
| Gene Expression Regulation, Plant | 6 | 2013 | 68 | 1.020 |
Why?
|
| Placenta Previa | 7 | 2024 | 67 | 1.000 |
Why?
|
| Obstetrics and Gynecology Department, Hospital | 4 | 2016 | 16 | 0.990 |
Why?
|
| Prenatal Care | 4 | 2020 | 359 | 0.990 |
Why?
|
| Guideline Adherence | 5 | 2016 | 399 | 0.970 |
Why?
|
| Extraction, Obstetrical | 3 | 2016 | 9 | 0.930 |
Why?
|
| Premature Birth | 4 | 2020 | 418 | 0.920 |
Why?
|
| Malpractice | 3 | 2011 | 59 | 0.900 |
Why?
|
| Patient Safety | 5 | 2016 | 433 | 0.890 |
Why?
|
| Receptors, Interleukin-6 | 1 | 2024 | 44 | 0.890 |
Why?
|
| Apgar Score | 3 | 2021 | 49 | 0.850 |
Why?
|
| United States | 33 | 2020 | 11762 | 0.840 |
Why?
|
| Clinical Protocols | 6 | 2015 | 245 | 0.840 |
Why?
|
| Pregnancy Complications, Hematologic | 3 | 2021 | 29 | 0.790 |
Why?
|
| Phosphoprotein Phosphatases | 4 | 2010 | 127 | 0.770 |
Why?
|
| Healthcare Disparities | 2 | 2017 | 481 | 0.740 |
Why?
|
| Thymus Neoplasms | 1 | 2022 | 40 | 0.740 |
Why?
|
| Infant, Newborn | 23 | 2024 | 8617 | 0.740 |
Why?
|
| Quality Assurance, Health Care | 6 | 2019 | 221 | 0.730 |
Why?
|
| Anticoagulants | 4 | 2024 | 615 | 0.720 |
Why?
|
| Umbilical Arteries | 1 | 2021 | 98 | 0.710 |
Why?
|
| Clinical Decision-Making | 3 | 2018 | 298 | 0.710 |
Why?
|
| Hysterectomy | 8 | 2022 | 201 | 0.700 |
Why?
|
| Postoperative Complications | 5 | 2019 | 3178 | 0.700 |
Why?
|
| Brachial Plexus | 1 | 2021 | 20 | 0.690 |
Why?
|
| Practice Guidelines as Topic | 10 | 2024 | 1340 | 0.680 |
Why?
|
| Radiologic Health | 1 | 2020 | 1 | 0.680 |
Why?
|
| Surgical Procedures, Operative | 2 | 2020 | 191 | 0.670 |
Why?
|
| Delivery of Health Care | 4 | 2019 | 680 | 0.660 |
Why?
|
| Algorithms | 6 | 2017 | 1735 | 0.650 |
Why?
|
| Acidosis | 2 | 2021 | 104 | 0.640 |
Why?
|
| Quality of Health Care | 6 | 2019 | 420 | 0.640 |
Why?
|
| Abortion, Spontaneous | 1 | 2020 | 85 | 0.620 |
Why?
|
| Cholecystectomy | 1 | 2019 | 64 | 0.620 |
Why?
|
| Antisepsis | 1 | 2018 | 8 | 0.600 |
Why?
|
| Povidone-Iodine | 1 | 2018 | 10 | 0.600 |
Why?
|
| Shock | 1 | 2020 | 99 | 0.600 |
Why?
|
| Peer Review | 2 | 2016 | 41 | 0.590 |
Why?
|
| Stillbirth | 3 | 2018 | 103 | 0.590 |
Why?
|
| Obstetrical Forceps | 2 | 2016 | 8 | 0.590 |
Why?
|
| Chlorhexidine | 1 | 2018 | 49 | 0.590 |
Why?
|
| Adult | 36 | 2024 | 31930 | 0.580 |
Why?
|
| Hospitals | 2 | 2019 | 437 | 0.580 |
Why?
|
| Intermittent Pneumatic Compression Devices | 2 | 2015 | 3 | 0.580 |
Why?
|
| Maternal-Fetal Exchange | 2 | 2016 | 85 | 0.580 |
Why?
|
| Evidence-Based Medicine | 5 | 2024 | 682 | 0.570 |
Why?
|
| Anti-Infective Agents, Local | 1 | 2018 | 71 | 0.570 |
Why?
|
| Liability, Legal | 1 | 2018 | 50 | 0.560 |
Why?
|
| Diagnostic Imaging | 1 | 2020 | 317 | 0.560 |
Why?
|
| Heart Arrest | 3 | 2019 | 374 | 0.550 |
Why?
|
| Women's Health Services | 1 | 2017 | 14 | 0.550 |
Why?
|
| Research Design | 3 | 2018 | 748 | 0.550 |
Why?
|
| Birth Injuries | 2 | 2008 | 22 | 0.550 |
Why?
|
| Hypoxia | 2 | 2016 | 268 | 0.550 |
Why?
|
| Blood Coagulation Disorders | 4 | 2021 | 110 | 0.540 |
Why?
|
| Ethanol | 1 | 2018 | 170 | 0.540 |
Why?
|
| Risk Factors | 16 | 2024 | 11180 | 0.530 |
Why?
|
| Term Birth | 3 | 2017 | 35 | 0.530 |
Why?
|
| Professional Staff Committees | 1 | 2016 | 6 | 0.530 |
Why?
|
| Maternal-Child Health Services | 1 | 2016 | 13 | 0.530 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 3 | 2010 | 148 | 0.520 |
Why?
|
| Birth Certificates | 1 | 2016 | 13 | 0.520 |
Why?
|
| Infertility, Female | 1 | 2017 | 151 | 0.520 |
Why?
|
| Amniotic Fluid | 1 | 2017 | 154 | 0.510 |
Why?
|
| Retrospective Studies | 28 | 2024 | 17538 | 0.510 |
Why?
|
| Perinatal Care | 2 | 2016 | 68 | 0.510 |
Why?
|
| Maternal Health Services | 3 | 2019 | 43 | 0.490 |
Why?
|
| Postnatal Care | 2 | 2015 | 52 | 0.490 |
Why?
|
| Surgical Wound Infection | 1 | 2018 | 275 | 0.490 |
Why?
|
| Cardiopulmonary Resuscitation | 2 | 2019 | 331 | 0.490 |
Why?
|
| Stem Cells | 3 | 2010 | 754 | 0.480 |
Why?
|
| Patient Care Bundles | 1 | 2015 | 26 | 0.480 |
Why?
|
| Hypertension | 2 | 2022 | 1398 | 0.470 |
Why?
|
| Simulation Training | 2 | 2019 | 146 | 0.470 |
Why?
|
| Education, Nursing | 1 | 2015 | 17 | 0.460 |
Why?
|
| Hospitalists | 1 | 2015 | 46 | 0.450 |
Why?
|
| Multigene Family | 4 | 2011 | 324 | 0.450 |
Why?
|
| Enterobacteriaceae Infections | 1 | 2015 | 59 | 0.450 |
Why?
|
| Maternal Age | 5 | 2020 | 140 | 0.450 |
Why?
|
| Infant, Newborn, Diseases | 1 | 2016 | 182 | 0.440 |
Why?
|
| Blood Component Transfusion | 5 | 2021 | 58 | 0.440 |
Why?
|
| Homeodomain Proteins | 5 | 2013 | 585 | 0.430 |
Why?
|
| Prenatal Diagnosis | 4 | 2021 | 632 | 0.430 |
Why?
|
| Blood Transfusion | 4 | 2021 | 323 | 0.420 |
Why?
|
| Pregnancy Complications, Infectious | 2 | 2017 | 486 | 0.420 |
Why?
|
| Magnesium Sulfate | 2 | 2011 | 50 | 0.410 |
Why?
|
| Epithelial Cells | 1 | 2017 | 937 | 0.410 |
Why?
|
| Elective Surgical Procedures | 2 | 2011 | 170 | 0.400 |
Why?
|
| Escherichia coli Infections | 1 | 2015 | 195 | 0.400 |
Why?
|
| Biometry | 1 | 2013 | 106 | 0.400 |
Why?
|
| Blood Gas Analysis | 3 | 2021 | 85 | 0.400 |
Why?
|
| beta-Lactamases | 1 | 2015 | 207 | 0.400 |
Why?
|
| Membrane Proteins | 2 | 2010 | 1613 | 0.390 |
Why?
|
| Infant, Low Birth Weight | 2 | 2011 | 176 | 0.390 |
Why?
|
| Personnel Staffing and Scheduling | 1 | 2013 | 83 | 0.380 |
Why?
|
| Nursing Staff, Hospital | 1 | 2013 | 67 | 0.380 |
Why?
|
| Plant Roots | 2 | 2010 | 31 | 0.380 |
Why?
|
| Drug Resistance, Bacterial | 1 | 2015 | 385 | 0.380 |
Why?
|
| Intensive Care Units, Neonatal | 2 | 2014 | 330 | 0.370 |
Why?
|
| Patient Compliance | 1 | 2015 | 481 | 0.360 |
Why?
|
| Patient Education as Topic | 1 | 2015 | 469 | 0.360 |
Why?
|
| Fetal Membranes, Premature Rupture | 2 | 2024 | 62 | 0.350 |
Why?
|
| Lung | 2 | 2017 | 1576 | 0.350 |
Why?
|
| Serine Proteases | 1 | 2010 | 8 | 0.350 |
Why?
|
| Medical Errors | 1 | 2012 | 162 | 0.350 |
Why?
|
| Lipoylation | 1 | 2010 | 5 | 0.350 |
Why?
|
| Oxygen | 2 | 2021 | 582 | 0.340 |
Why?
|
| Checklist | 3 | 2017 | 95 | 0.340 |
Why?
|
| Dystocia | 2 | 2008 | 24 | 0.340 |
Why?
|
| Fetal Death | 3 | 2018 | 121 | 0.330 |
Why?
|
| Diagnosis, Differential | 5 | 2018 | 1978 | 0.330 |
Why?
|
| Biomedical Research | 1 | 2016 | 556 | 0.330 |
Why?
|
| Quality Improvement | 1 | 2016 | 700 | 0.330 |
Why?
|
| Protease Inhibitors | 1 | 2010 | 100 | 0.330 |
Why?
|
| Consensus | 4 | 2019 | 732 | 0.330 |
Why?
|
| Protein Precursors | 1 | 2010 | 155 | 0.330 |
Why?
|
| Hydrogen-Ion Concentration | 4 | 2019 | 470 | 0.320 |
Why?
|
| Placenta Diseases | 2 | 2022 | 61 | 0.320 |
Why?
|
| Neuroprotective Agents | 1 | 2011 | 169 | 0.310 |
Why?
|
| Postpartum Period | 2 | 2010 | 229 | 0.310 |
Why?
|
| Group Practice | 1 | 2009 | 12 | 0.310 |
Why?
|
| Infant, Premature, Diseases | 1 | 2011 | 254 | 0.310 |
Why?
|
| Compensation and Redress | 1 | 2008 | 12 | 0.310 |
Why?
|
| Intraoperative Complications | 2 | 2021 | 165 | 0.300 |
Why?
|
| Uterine Contraction | 1 | 2008 | 29 | 0.300 |
Why?
|
| Fetal Hypoxia | 2 | 2011 | 14 | 0.290 |
Why?
|
| Sleep Deprivation | 1 | 2009 | 56 | 0.290 |
Why?
|
| Vacuum Extraction, Obstetrical | 1 | 2008 | 3 | 0.290 |
Why?
|
| Sensitivity and Specificity | 5 | 2021 | 2172 | 0.290 |
Why?
|
| Infant, Premature | 2 | 2011 | 858 | 0.280 |
Why?
|
| Placenta | 5 | 2022 | 536 | 0.270 |
Why?
|
| Pregnancy Trimester, Third | 3 | 2019 | 124 | 0.270 |
Why?
|
| Flowers | 2 | 2006 | 11 | 0.270 |
Why?
|
| Young Adult | 9 | 2024 | 9935 | 0.270 |
Why?
|
| Shoulder | 1 | 2006 | 33 | 0.260 |
Why?
|
| Fetal Diseases | 1 | 2011 | 462 | 0.260 |
Why?
|
| Clinical Competence | 2 | 2016 | 1062 | 0.260 |
Why?
|
| Nervous System Diseases | 1 | 2011 | 410 | 0.260 |
Why?
|
| Leucine Zippers | 1 | 2006 | 18 | 0.260 |
Why?
|
| Genes, Plant | 4 | 2008 | 40 | 0.250 |
Why?
|
| Phosphoric Monoester Hydrolases | 1 | 2006 | 109 | 0.250 |
Why?
|
| Fetus | 2 | 2021 | 601 | 0.250 |
Why?
|
| Oximetry | 1 | 2007 | 179 | 0.250 |
Why?
|
| Vena Cava Filters | 1 | 2005 | 17 | 0.240 |
Why?
|
| Heart Defects, Congenital | 1 | 2017 | 1879 | 0.240 |
Why?
|
| Labetalol | 2 | 2020 | 12 | 0.230 |
Why?
|
| Oxygen Inhalation Therapy | 2 | 2021 | 93 | 0.230 |
Why?
|
| Thromboembolism | 1 | 2005 | 92 | 0.230 |
Why?
|
| Cesarean Section, Repeat | 1 | 2024 | 8 | 0.230 |
Why?
|
| Labor Stage, Second | 2 | 2021 | 16 | 0.230 |
Why?
|
| Uterine Hemorrhage | 2 | 2019 | 43 | 0.230 |
Why?
|
| Patient Selection | 2 | 2020 | 735 | 0.220 |
Why?
|
| Cohort Studies | 6 | 2022 | 5217 | 0.220 |
Why?
|
| Cerebrovascular Circulation | 3 | 2020 | 474 | 0.220 |
Why?
|
| Vaginal Birth after Cesarean | 2 | 2018 | 23 | 0.220 |
Why?
|
| Organ Preservation | 1 | 2024 | 50 | 0.220 |
Why?
|
| Enoxaparin | 1 | 2024 | 48 | 0.220 |
Why?
|
| Gene Expression Regulation, Developmental | 4 | 2013 | 1051 | 0.210 |
Why?
|
| Registries | 3 | 2020 | 1578 | 0.210 |
Why?
|
| Value of Life | 1 | 2003 | 9 | 0.210 |
Why?
|
| Erythrocyte Transfusion | 3 | 2019 | 135 | 0.210 |
Why?
|
| Perfusion | 1 | 2024 | 214 | 0.210 |
Why?
|
| Hypoxia-Ischemia, Brain | 1 | 2024 | 83 | 0.200 |
Why?
|
| Infusions, Intravenous | 3 | 2020 | 572 | 0.200 |
Why?
|
| Perineum | 3 | 2021 | 48 | 0.200 |
Why?
|
| Evolution, Molecular | 1 | 2006 | 710 | 0.200 |
Why?
|
| Molecular Sequence Data | 4 | 2010 | 3979 | 0.200 |
Why?
|
| Antirheumatic Agents | 1 | 2024 | 124 | 0.200 |
Why?
|
| Prospective Studies | 9 | 2021 | 6601 | 0.190 |
Why?
|
| Time Factors | 4 | 2018 | 6610 | 0.190 |
Why?
|
| Pregnancy Trimesters | 2 | 2021 | 34 | 0.190 |
Why?
|
| Emergency Service, Hospital | 1 | 2010 | 1156 | 0.190 |
Why?
|
| Pregnancy, Twin | 2 | 2021 | 189 | 0.190 |
Why?
|
| Eclampsia | 2 | 2020 | 29 | 0.190 |
Why?
|
| Infant Mortality | 3 | 2016 | 180 | 0.180 |
Why?
|
| Labor Presentation | 1 | 2021 | 10 | 0.180 |
Why?
|
| Cerebral Palsy | 1 | 2003 | 85 | 0.180 |
Why?
|
| Risk Assessment | 4 | 2020 | 3742 | 0.180 |
Why?
|
| Urologic Diseases | 1 | 2021 | 45 | 0.180 |
Why?
|
| Fetal Distress | 2 | 2016 | 12 | 0.180 |
Why?
|
| Ovulation Induction | 1 | 2021 | 42 | 0.180 |
Why?
|
| Arthritis, Rheumatoid | 1 | 2024 | 296 | 0.170 |
Why?
|
| Ultrasonography, Prenatal | 3 | 2021 | 1000 | 0.170 |
Why?
|
| Incidence | 4 | 2022 | 3416 | 0.170 |
Why?
|
| Nifedipine | 1 | 2020 | 21 | 0.170 |
Why?
|
| Signal Transduction | 6 | 2011 | 4934 | 0.160 |
Why?
|
| History, 21st Century | 2 | 2014 | 277 | 0.160 |
Why?
|
| Risk Adjustment | 1 | 2020 | 60 | 0.160 |
Why?
|
| Phylogeny | 3 | 2011 | 785 | 0.160 |
Why?
|
| Blood Coagulation | 1 | 2021 | 134 | 0.160 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2024 | 556 | 0.160 |
Why?
|
| Amino Acid Sequence | 3 | 2010 | 2794 | 0.160 |
Why?
|
| Referral and Consultation | 2 | 2015 | 574 | 0.160 |
Why?
|
| Case-Control Studies | 4 | 2019 | 3667 | 0.160 |
Why?
|
| Vasa Previa | 1 | 2019 | 9 | 0.160 |
Why?
|
| Remission, Spontaneous | 1 | 2019 | 69 | 0.160 |
Why?
|
| Patient Care Team | 3 | 2019 | 574 | 0.160 |
Why?
|
| Hospital Administration | 1 | 2019 | 25 | 0.150 |
Why?
|
| Fetal Hemoglobin | 1 | 2019 | 28 | 0.150 |
Why?
|
| Cause of Death | 2 | 2014 | 507 | 0.150 |
Why?
|
| Bicarbonates | 1 | 2019 | 100 | 0.150 |
Why?
|
| Obstetric Labor, Premature | 1 | 2019 | 85 | 0.150 |
Why?
|
| Nomograms | 1 | 2019 | 38 | 0.150 |
Why?
|
| Perinatology | 1 | 2019 | 35 | 0.150 |
Why?
|
| Fertilization in Vitro | 1 | 2020 | 163 | 0.150 |
Why?
|
| Administration, Cutaneous | 1 | 2018 | 68 | 0.150 |
Why?
|
| Cross-Sectional Studies | 5 | 2021 | 3754 | 0.150 |
Why?
|
| Birth Weight | 4 | 2022 | 354 | 0.150 |
Why?
|
| Plant Leaves | 2 | 2010 | 54 | 0.140 |
Why?
|
| Fetal Blood | 1 | 2019 | 178 | 0.140 |
Why?
|
| Delayed Diagnosis | 1 | 2019 | 135 | 0.140 |
Why?
|
| Fetal Mortality | 1 | 2017 | 7 | 0.140 |
Why?
|
| Episiotomy | 1 | 2017 | 17 | 0.140 |
Why?
|
| Drug Combinations | 1 | 2018 | 285 | 0.140 |
Why?
|
| Cell Count | 1 | 2017 | 241 | 0.140 |
Why?
|
| Guidelines as Topic | 1 | 2018 | 203 | 0.140 |
Why?
|
| Heart Transplantation | 1 | 2024 | 904 | 0.140 |
Why?
|
| Prognosis | 4 | 2019 | 5086 | 0.130 |
Why?
|
| Learning Curve | 1 | 2017 | 57 | 0.130 |
Why?
|
| Health Status Indicators | 1 | 2017 | 130 | 0.130 |
Why?
|
| Peripartum Period | 1 | 2016 | 29 | 0.130 |
Why?
|
| Birth Rate | 1 | 2016 | 17 | 0.130 |
Why?
|
| Epidemics | 1 | 2017 | 59 | 0.130 |
Why?
|
| Benchmarking | 1 | 2017 | 147 | 0.130 |
Why?
|
| Communicable Diseases, Emerging | 1 | 2017 | 67 | 0.130 |
Why?
|
| Maternal-Fetal Relations | 1 | 2016 | 16 | 0.130 |
Why?
|
| Medical Records | 2 | 2014 | 194 | 0.120 |
Why?
|
| Preoperative Care | 1 | 2018 | 376 | 0.120 |
Why?
|
| Parturition | 1 | 2016 | 67 | 0.120 |
Why?
|
| Interdisciplinary Communication | 1 | 2017 | 135 | 0.120 |
Why?
|
| Terminology as Topic | 2 | 2015 | 234 | 0.120 |
Why?
|
| New York | 1 | 2015 | 73 | 0.120 |
Why?
|
| Police | 1 | 2015 | 14 | 0.120 |
Why?
|
| Hypotension | 2 | 2016 | 190 | 0.120 |
Why?
|
| Bradycardia | 1 | 2016 | 63 | 0.120 |
Why?
|
| Congresses as Topic | 1 | 2016 | 187 | 0.120 |
Why?
|
| Pneumothorax | 1 | 2016 | 82 | 0.120 |
Why?
|
| Quality Indicators, Health Care | 1 | 2017 | 231 | 0.120 |
Why?
|
| Congenital Abnormalities | 1 | 2018 | 295 | 0.120 |
Why?
|
| Reproduction | 1 | 2017 | 245 | 0.110 |
Why?
|
| Zika Virus Infection | 1 | 2017 | 175 | 0.110 |
Why?
|
| Thrombocytopenia | 1 | 2016 | 237 | 0.110 |
Why?
|
| Joint Commission on Accreditation of Healthcare Organizations | 1 | 2014 | 5 | 0.110 |
Why?
|
| Cephalosporins | 1 | 2015 | 142 | 0.110 |
Why?
|
| Protein Phosphatase 2C | 2 | 2005 | 60 | 0.110 |
Why?
|
| Hemorrhage | 2 | 2021 | 513 | 0.110 |
Why?
|
| Transportation of Patients | 1 | 2014 | 54 | 0.110 |
Why?
|
| Continuity of Patient Care | 1 | 2015 | 153 | 0.110 |
Why?
|
| Menstrual Cycle | 1 | 2013 | 37 | 0.100 |
Why?
|
| Patient Admission | 1 | 2014 | 190 | 0.100 |
Why?
|
| Asphyxia Neonatorum | 1 | 2013 | 16 | 0.100 |
Why?
|
| Hospital Mortality | 1 | 2018 | 1096 | 0.100 |
Why?
|
| Triage | 1 | 2014 | 148 | 0.100 |
Why?
|
| Plasma | 3 | 2019 | 105 | 0.100 |
Why?
|
| Disease Management | 1 | 2016 | 566 | 0.100 |
Why?
|
| Extracorporeal Membrane Oxygenation | 1 | 2019 | 642 | 0.100 |
Why?
|
| Decision Support Techniques | 1 | 2015 | 319 | 0.100 |
Why?
|
| Costs and Cost Analysis | 1 | 2013 | 165 | 0.100 |
Why?
|
| Uterine Inertia | 1 | 2012 | 5 | 0.100 |
Why?
|
| Oliguria | 1 | 2012 | 20 | 0.100 |
Why?
|
| History, 20th Century | 1 | 2014 | 396 | 0.090 |
Why?
|
| Treatment Outcome | 4 | 2024 | 13074 | 0.090 |
Why?
|
| Furosemide | 1 | 2012 | 37 | 0.090 |
Why?
|
| Mutation | 4 | 2008 | 6316 | 0.090 |
Why?
|
| Contraindications | 1 | 2012 | 79 | 0.090 |
Why?
|
| Pregnancy, Prolonged | 1 | 2011 | 3 | 0.090 |
Why?
|
| Microbial Sensitivity Tests | 1 | 2015 | 834 | 0.090 |
Why?
|
| Workload | 1 | 2013 | 151 | 0.090 |
Why?
|
| Misoprostol | 2 | 2009 | 27 | 0.090 |
Why?
|
| ROC Curve | 2 | 2019 | 611 | 0.090 |
Why?
|
| Decision Making | 1 | 2017 | 701 | 0.090 |
Why?
|
| Clinical Trials as Topic | 1 | 2016 | 1157 | 0.090 |
Why?
|
| Medical Audit | 1 | 2012 | 104 | 0.090 |
Why?
|
| Crops, Agricultural | 1 | 2011 | 20 | 0.090 |
Why?
|
| Tocolysis | 1 | 2011 | 5 | 0.090 |
Why?
|
| Angiography | 1 | 2012 | 215 | 0.090 |
Why?
|
| Tennessee | 1 | 2011 | 34 | 0.090 |
Why?
|
| Tocolytic Agents | 1 | 2011 | 12 | 0.090 |
Why?
|
| Chest Pain | 1 | 2012 | 133 | 0.090 |
Why?
|
| Carboxypeptidases | 1 | 2010 | 20 | 0.090 |
Why?
|
| Respiratory Tract Diseases | 1 | 2011 | 81 | 0.090 |
Why?
|
| Diuretics | 1 | 2012 | 169 | 0.090 |
Why?
|
| Anticonvulsants | 2 | 2020 | 393 | 0.090 |
Why?
|
| Adolescent | 5 | 2024 | 20610 | 0.090 |
Why?
|
| Brassica | 1 | 2010 | 17 | 0.090 |
Why?
|
| Urinary Tract Infections | 1 | 2015 | 307 | 0.090 |
Why?
|
| Acylation | 1 | 2010 | 17 | 0.090 |
Why?
|
| Models, Biological | 2 | 2008 | 1539 | 0.090 |
Why?
|
| Dyspnea | 1 | 2012 | 160 | 0.090 |
Why?
|
| Morbidity | 1 | 2011 | 256 | 0.090 |
Why?
|
| Neonatology | 1 | 2011 | 57 | 0.080 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 1 | 2010 | 311 | 0.080 |
Why?
|
| Jaundice, Neonatal | 1 | 2010 | 10 | 0.080 |
Why?
|
| Immunoblotting | 1 | 2010 | 319 | 0.080 |
Why?
|
| Plant Proteins | 1 | 2010 | 91 | 0.080 |
Why?
|
| Immunoprecipitation | 1 | 2010 | 206 | 0.080 |
Why?
|
| Glutathione Transferase | 1 | 2010 | 163 | 0.080 |
Why?
|
| Multivariate Analysis | 2 | 2020 | 1492 | 0.080 |
Why?
|
| Analysis of Variance | 2 | 2010 | 1044 | 0.080 |
Why?
|
| Middle Aged | 5 | 2024 | 29394 | 0.080 |
Why?
|
| Cholecystitis | 1 | 2009 | 21 | 0.080 |
Why?
|
| Cooperative Behavior | 1 | 2011 | 233 | 0.080 |
Why?
|
| Hemodynamics | 1 | 2014 | 873 | 0.080 |
Why?
|
| Puerperal Disorders | 1 | 2009 | 47 | 0.080 |
Why?
|
| Pneumonia | 2 | 2011 | 343 | 0.080 |
Why?
|
| Leucine | 1 | 2010 | 312 | 0.080 |
Why?
|
| Bilirubin | 1 | 2010 | 131 | 0.080 |
Why?
|
| Utah | 2 | 2006 | 83 | 0.080 |
Why?
|
| Protein Transport | 1 | 2010 | 390 | 0.080 |
Why?
|
| Platelet Transfusion | 2 | 2019 | 54 | 0.080 |
Why?
|
| Mass Spectrometry | 1 | 2010 | 370 | 0.080 |
Why?
|
| Microscopy, Confocal | 1 | 2010 | 366 | 0.080 |
Why?
|
| Chi-Square Distribution | 1 | 2010 | 606 | 0.080 |
Why?
|
| Uterine Rupture | 1 | 2009 | 18 | 0.080 |
Why?
|
| Arginine | 1 | 2010 | 351 | 0.070 |
Why?
|
| Neonatal Screening | 1 | 2010 | 193 | 0.070 |
Why?
|
| Appendicitis | 1 | 2009 | 130 | 0.070 |
Why?
|
| Blood Volume | 1 | 2008 | 83 | 0.070 |
Why?
|
| Patient Readmission | 2 | 2009 | 429 | 0.070 |
Why?
|
| Hospitals, Proprietary | 1 | 2007 | 2 | 0.070 |
Why?
|
| Binding Sites | 1 | 2010 | 1383 | 0.070 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2010 | 806 | 0.070 |
Why?
|
| DNA, Plant | 1 | 2006 | 12 | 0.070 |
Why?
|
| Heart Diseases | 1 | 2012 | 526 | 0.070 |
Why?
|
| Genetic Complementation Test | 1 | 2006 | 90 | 0.070 |
Why?
|
| Internship and Residency | 1 | 2017 | 1250 | 0.070 |
Why?
|
| Male | 7 | 2024 | 66093 | 0.060 |
Why?
|
| Epistasis, Genetic | 1 | 2006 | 103 | 0.060 |
Why?
|
| Factor VIII | 2 | 2019 | 49 | 0.060 |
Why?
|
| Protein Binding | 1 | 2010 | 1858 | 0.060 |
Why?
|
| Animals | 4 | 2014 | 36545 | 0.060 |
Why?
|
| Oxygen Consumption | 1 | 2007 | 317 | 0.060 |
Why?
|
| Plant Structures | 1 | 2005 | 4 | 0.060 |
Why?
|
| Fibrinogen | 2 | 2019 | 163 | 0.060 |
Why?
|
| Uterus | 1 | 2009 | 586 | 0.060 |
Why?
|
| Cells, Cultured | 1 | 2010 | 3187 | 0.060 |
Why?
|
| Disease Models, Animal | 2 | 2014 | 4807 | 0.060 |
Why?
|
| Critical Care | 1 | 2010 | 693 | 0.060 |
Why?
|
| Primary Graft Dysfunction | 1 | 2024 | 26 | 0.060 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 2005 | 261 | 0.060 |
Why?
|
| Transfusion Reaction | 2 | 2015 | 40 | 0.050 |
Why?
|
| Gene Dosage | 1 | 2005 | 458 | 0.050 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2012 | 2198 | 0.050 |
Why?
|
| Logistic Models | 2 | 2019 | 1909 | 0.050 |
Why?
|
| Emergencies | 2 | 2017 | 187 | 0.050 |
Why?
|
| Probability | 3 | 2015 | 334 | 0.050 |
Why?
|
| Meconium | 1 | 2002 | 12 | 0.050 |
Why?
|
| Developed Countries | 1 | 2003 | 42 | 0.050 |
Why?
|
| Oryza | 1 | 2003 | 29 | 0.050 |
Why?
|
| Tissue Distribution | 1 | 2003 | 402 | 0.050 |
Why?
|
| Infant Welfare | 1 | 2002 | 28 | 0.050 |
Why?
|
| Maternal Welfare | 1 | 2002 | 14 | 0.050 |
Why?
|
| Base Sequence | 1 | 2006 | 3178 | 0.050 |
Why?
|
| Protein Kinases | 1 | 2004 | 345 | 0.050 |
Why?
|
| Anesthesia, Epidural | 1 | 2002 | 18 | 0.050 |
Why?
|
| Pelvis | 1 | 2022 | 74 | 0.050 |
Why?
|
| Reproducibility of Results | 2 | 2021 | 3043 | 0.050 |
Why?
|
| Anesthesia, Obstetrical | 1 | 2002 | 37 | 0.050 |
Why?
|
| Receptors, Cell Surface | 1 | 2004 | 497 | 0.050 |
Why?
|
| Sequence Alignment | 1 | 2003 | 633 | 0.050 |
Why?
|
| Fertilization | 1 | 2021 | 45 | 0.040 |
Why?
|
| Predictive Value of Tests | 1 | 2006 | 2301 | 0.040 |
Why?
|
| Infant | 1 | 2016 | 13230 | 0.040 |
Why?
|
| Blood Coagulation Tests | 1 | 2021 | 62 | 0.040 |
Why?
|
| Tissue Donors | 1 | 2024 | 523 | 0.040 |
Why?
|
| Severity of Illness Index | 2 | 2019 | 3114 | 0.040 |
Why?
|
| Alleles | 1 | 2005 | 1716 | 0.040 |
Why?
|
| Placentation | 1 | 2020 | 61 | 0.040 |
Why?
|
| Causality | 1 | 2020 | 94 | 0.040 |
Why?
|
| Thrombelastography | 1 | 2021 | 60 | 0.040 |
Why?
|
| Cost-Benefit Analysis | 1 | 2003 | 563 | 0.040 |
Why?
|
| Graft Rejection | 1 | 2024 | 630 | 0.040 |
Why?
|
| Texas | 2 | 2020 | 3716 | 0.040 |
Why?
|
| Odds Ratio | 2 | 2020 | 1338 | 0.040 |
Why?
|
| Genetic Diseases, Inborn | 1 | 2024 | 461 | 0.040 |
Why?
|
| Ultrasonography, Doppler, Transcranial | 1 | 2020 | 119 | 0.040 |
Why?
|
| Health Care Costs | 1 | 2003 | 408 | 0.040 |
Why?
|
| Hemoglobin A | 1 | 2019 | 22 | 0.040 |
Why?
|
| Disseminated Intravascular Coagulation | 1 | 2019 | 67 | 0.040 |
Why?
|
| Exome | 1 | 2024 | 1075 | 0.040 |
Why?
|
| Acid-Base Imbalance | 1 | 2019 | 27 | 0.040 |
Why?
|
| Cell Differentiation | 1 | 2006 | 2044 | 0.040 |
Why?
|
| Acid-Base Equilibrium | 1 | 2019 | 61 | 0.040 |
Why?
|
| Emergency Medical Services | 1 | 2003 | 414 | 0.040 |
Why?
|
| Vasoconstrictor Agents | 1 | 2019 | 146 | 0.040 |
Why?
|
| Live Birth | 1 | 2018 | 72 | 0.040 |
Why?
|
| Academic Medical Centers | 1 | 2020 | 333 | 0.040 |
Why?
|
| Proteins | 1 | 2004 | 1099 | 0.040 |
Why?
|
| Administration, Oral | 1 | 2020 | 727 | 0.040 |
Why?
|
| Placenta, Retained | 1 | 2017 | 12 | 0.040 |
Why?
|
| Follow-Up Studies | 1 | 2007 | 5477 | 0.030 |
Why?
|
| Inservice Training | 1 | 2017 | 56 | 0.030 |
Why?
|
| Hospitals, University | 1 | 2017 | 106 | 0.030 |
Why?
|
| Research | 1 | 2019 | 272 | 0.030 |
Why?
|
| Isotonic Solutions | 1 | 2017 | 36 | 0.030 |
Why?
|
| Parity | 1 | 2017 | 89 | 0.030 |
Why?
|
| Gravidity | 1 | 2016 | 12 | 0.030 |
Why?
|
| Breech Presentation | 1 | 2016 | 20 | 0.030 |
Why?
|
| Population | 1 | 2016 | 24 | 0.030 |
Why?
|
| Family | 1 | 2019 | 592 | 0.030 |
Why?
|
| Health Status Disparities | 1 | 2019 | 250 | 0.030 |
Why?
|
| Prevalence | 1 | 2003 | 2684 | 0.030 |
Why?
|
| Length of Stay | 1 | 2002 | 1391 | 0.030 |
Why?
|
| Databases as Topic | 1 | 2015 | 77 | 0.030 |
Why?
|
| Fellowships and Scholarships | 1 | 2019 | 314 | 0.030 |
Why?
|
| Seizures | 1 | 2020 | 890 | 0.030 |
Why?
|
| Signal Processing, Computer-Assisted | 1 | 2015 | 133 | 0.030 |
Why?
|
| Hemostatics | 1 | 2015 | 63 | 0.030 |
Why?
|
| Databases, Factual | 1 | 2020 | 1258 | 0.030 |
Why?
|
| Fluid Therapy | 1 | 2015 | 149 | 0.030 |
Why?
|
| Hypertension, Pulmonary | 1 | 2019 | 475 | 0.030 |
Why?
|
| Education, Medical, Graduate | 1 | 2019 | 560 | 0.030 |
Why?
|
| Microcephaly | 1 | 2017 | 352 | 0.030 |
Why?
|
| Echocardiography | 1 | 2019 | 1131 | 0.030 |
Why?
|
| Monitoring, Physiologic | 1 | 2016 | 388 | 0.030 |
Why?
|
| Electronic Health Records | 1 | 2020 | 797 | 0.030 |
Why?
|
| Models, Theoretical | 1 | 2015 | 398 | 0.030 |
Why?
|
| Regional Medical Programs | 1 | 2012 | 17 | 0.020 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2024 | 3495 | 0.020 |
Why?
|
| Resuscitation | 1 | 2015 | 268 | 0.020 |
Why?
|
| Patient Discharge | 2 | 2010 | 519 | 0.020 |
Why?
|
| Combined Modality Therapy | 1 | 2015 | 1310 | 0.020 |
Why?
|
| Erythrocytes | 1 | 2012 | 238 | 0.020 |
Why?
|
| Pulmonary Edema | 1 | 2011 | 52 | 0.020 |
Why?
|
| Delivery of Health Care, Integrated | 1 | 2012 | 138 | 0.020 |
Why?
|
| Respiratory Function Tests | 1 | 2011 | 215 | 0.020 |
Why?
|
| Phototherapy | 1 | 2010 | 39 | 0.020 |
Why?
|
| Blood Platelets | 1 | 2012 | 342 | 0.020 |
Why?
|
| Prostaglandins | 1 | 2009 | 48 | 0.020 |
Why?
|
| Peer Review, Health Care | 1 | 2009 | 17 | 0.020 |
Why?
|
| Hematocrit | 1 | 2008 | 116 | 0.020 |
Why?
|
| Lacerations | 1 | 2008 | 33 | 0.020 |
Why?
|
| Pulsatile Flow | 1 | 2006 | 128 | 0.020 |
Why?
|
| Heart Failure | 1 | 2019 | 2437 | 0.020 |
Why?
|
| Multicenter Studies as Topic | 1 | 2006 | 294 | 0.020 |
Why?
|
| Aged | 1 | 2024 | 21772 | 0.020 |
Why?
|
| Asthma | 1 | 2011 | 810 | 0.010 |
Why?
|
| Goats | 1 | 2002 | 60 | 0.010 |
Why?
|
| False Negative Reactions | 1 | 2002 | 90 | 0.010 |
Why?
|
| Cervical Ripening | 1 | 2002 | 7 | 0.010 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2006 | 1218 | 0.010 |
Why?
|
| Confidence Intervals | 1 | 2002 | 300 | 0.010 |
Why?
|
| Child | 1 | 2022 | 25870 | 0.010 |
Why?
|
| Hospital Costs | 1 | 2002 | 187 | 0.010 |
Why?
|
| Reference Values | 1 | 2002 | 740 | 0.010 |
Why?
|
| Patient Satisfaction | 1 | 2002 | 490 | 0.010 |
Why?
|